Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | PPARG | P37231 | 4/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14563331 | 0.90 | CA2 (0.54) | CA2PPARGFFAR1MAPTPPARA | |
| SCHEMBL5246851 | 0.86 | CA2 (0.54) | CA2PPARGFFAR1MAPTPPARA | |
| SCHEMBL5246849 | 0.84 | CA2 (0.52) | CA2PPARGFFAR1MAPTPPARA | |
| SCHEMBL13846798 | 0.84 | ESR2 (0.59) | CA2PPARGMAPT | |
| SCHEMBL13846776 | 0.83 | CA2 (0.69) | CA2PPARGFFAR1MAPTPTPN1 | |
| SCHEMBL8317057 | 0.82 | PPARG (0.62) | PPARGFFAR1MAPTPPARA | |
| SCHEMBL13846817 | 0.81 | FFAR1 (0.55) | CA2PPARGFFAR1MAPTPTPN1 | |
| SCHEMBL5476047 | 0.79 | CHRM1 (0.54) | CA2PPARGFFAR1MAPTPTPN1 | |
| SCHEMBL6648526 | 0.78 | CA2 (0.50) | CA2PPARGFFAR1MAPTPPARA | |
| SCHEMBL6496500 | 0.78 | HPGD (0.53) | CA2PPARGMAPTPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070065472-A1 | Benzyl-1,3-thiazolidine-2,4-dione compounds for stimulating or inducing the growth and/or for reducing the loss of keratin fibers | L'OREAL (FR) | 2007-03-22 | — | — | US | claimed |
| EP-1738742-A2 | Benzyl-1,3-thiazolidine-2,4-dione compounds, compositions comprising them and use for stimulating or inducing the growth of keratinic fibres and/or for diminsihing their loss | L'Oréal (FR) | 2007-01-03 | — | — | EP | claimed |
| US-20070065472-A1 | Benzyl-1,3-thiazolidine-2,4-dione compounds for stimulating or inducing the growth and/or for reducing the loss of keratin fibers | L'OREAL (FR) | 2007-03-22 | — | — | US | disclosed |
| US-20070065472-A1 | Benzyl-1,3-thiazolidine-2,4-dione compounds for stimulating or inducing the growth and/or for reducing the loss of keratin fibers | L'OREAL (FR) | 2007-03-22 | — | — | US | disclosed |
| US-20070065472-A1 | Benzyl-1,3-thiazolidine-2,4-dione compounds for stimulating or inducing the growth and/or for reducing the loss of keratin fibers | L'OREAL (FR) | 2007-03-22 | — | — | US | disclosed |
| US-20070059260-A1 | Benzyl-1,3-thiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting their depigmentation and/or whitening | L'OREAL (FR) | 2007-03-15 | — | — | US | disclosed |
| US-20070059260-A1 | Benzyl-1,3-thiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting their depigmentation and/or whitening | L'OREAL (FR) | 2007-03-15 | — | — | US | disclosed |
| US-20070059260-A1 | Benzyl-1,3-thiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting their depigmentation and/or whitening | L'OREAL (FR) | 2007-03-15 | — | — | US | disclosed |
| EP-1738740-A2 | Use of benzyl-1,3-thiazolidine-2,4-dione compounds for favouring and/or inducing and/or stimulating the pigmentation of keratinic materials and/or for limiting their depigmentation and/or their bleaching | L'Oréal (FR) | 2007-01-03 | — | — | EP | disclosed |
| EP-1738742-A2 | Benzyl-1,3-thiazolidine-2,4-dione compounds, compositions comprising them and use for stimulating or inducing the growth of keratinic fibres and/or for diminsihing their loss | L'Oréal (FR) | 2007-01-03 | — | — | EP | disclosed |
| EP-1738742-A2 | Benzyl-1,3-thiazolidine-2,4-dione compounds, compositions comprising them and use for stimulating or inducing the growth of keratinic fibres and/or for diminsihing their loss | L'Oréal (FR) | 2007-01-03 | — | — | EP | disclosed |
| EP-1738740-A2 | Use of benzyl-1,3-thiazolidine-2,4-dione compounds for favouring and/or inducing and/or stimulating the pigmentation of keratinic materials and/or for limiting their depigmentation and/or their bleaching | L'Oréal (FR) | 2007-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070059260-A1 | Benzyl-1,3-thiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting their depigmentation and/or whitening | KRT18, TYR, MITF | CA2 488/4885PPARG 1196/4885FFAR1 3384/4885 |
| US-20070065472-A1 | Benzyl-1,3-thiazolidine-2,4-dione compounds for stimulating or inducing the growth and/or for reducing the loss of keratin fibers | KRT18, FGF1, BRD7 | CA2 737/4885PPARG 1487/4885FFAR1 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.